Plasma Articles
A growing body of evidence suggests known pharmacologic properties of human albumin may contribute to reducing the risk of a range of cirrhosis complications, including bacterial sepsis, irreversible renal injury and death.
Findings from Grifols’ Phase IIb Alzheimer Management by Albumin Replacement (AMBAR) clinical trial found long-term plasmapheresis with albumin replacement reduced disease progression in a prespecified subset of patients with AD of moderate severity.
Once thought to be a useless byproduct, umbilical cord blood now treats more than 80 diseases, and it may soon be used to treat more.
A potential solution for CIDP patients with these IVIG-related issues is self-administered subcutaneous immune globulin.
The success of IG manufacturing assures that today and in the future, patients in need have access to this unique therapeutic.
Researchers are taking a closer look at intravenous immune globulin for its potential to stop the progression of multiple complex conditions from lupus to multiple sclerosis.
The plasma donor is the first vital part of the process to produce safe and effective plasma protein therapeutics, and the industry prioritizes the safety and health of its plasma donors.
Usually developing following trauma, complex regional pain syndrome (CRPS) has been postulated to be associated with distal degeneration of small-diameter peripheral axons.
Grifols, the world’s third largest manufacturer of plasma-based therapeutics and a leader in immunohematology and transfusion medicine diagnostics, has been patiently developing a novel approach to treatment of AD, based on plasma exchange and replacement with donor human albumin.
Thirty years after its quiet introduction, unabated global research interest in IVIG reflects just how much remains unknown about its therapeutic potential.
The plasma industry continues to plan and invest for the future to assure that immunoglobulin, albumin and other life-critical plasma products are on the shelf when they’re needed.